title: Association between corneal temperature and mental status of treatment-resistant schizophrenia inpatients.
abstract: BACKGROUND
  Preliminary point-prevalent data suggest that drug-free schizophrenia patients may exhibit increased body/corneal temperature, that antipsychotic drugs (APDs) may decrease body/core temperature and that patients' mental status might be associated with their body/corneal temperature. Hence, we hypothesized that treatment-resistant psychotic APD-treated schizophrenia patients' mental status may correlate with their corneal temperature during a continuous 6-week period.
  
  
  METHODS
  Corneal temperature of 12 treatment-resistant schizophrenia inpatients and 16 healthy volunteers was evaluated 2-3 times a week during 6 consecutive weeks using a flir thermal imaging camera.
  
  
  RESULTS
  A significant and substantial correlation was found between inpatients' mean weekly Positive and Negative Syndrome Scale (PANSS)'s total scores and their mean weekly corneal temperature during the 6-week study period (r=0.82; n=6 weeks; p=0.043). There was no significant difference in mean 6-week corneal temperature between the patient group and the healthy subjects (34.25+/-0.64 degrees C vs. 34.39+/-0.69 degrees C, respectively; t=1.127, df=131, p=0.26).
  
  
  CONCLUSIONS
  This study indicates that treatment-resistant overtly psychotic schizophrenia inpatients' mental status (as assessed by the PANSS) correlates with their corneal temperature. The relevance of these phenomena to the pathophysiology of schizophrenia, the biological mechanism underlying corneal temperature alterations and the possible role of temperature-modulating drugs (neuroleptics or non-neuroleptics) on schizophrenic psychosis merits further large-scale investigation in both medicated- and drug-free schizophrenia patients compared to matched controls.
authors.affiliation: Geha Mental Health Center, Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus, Petach-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. ronishiloh@gmail.com
authors.forename: Roni
authors.initials: R
authors.lastname: Shiloh
authors.forename: Lior
authors.initials: L
authors.lastname: Schapir
authors.forename: Danit
authors.initials: D
authors.lastname: Bar-Ziv
authors.forename: Rafael
authors.initials: R
authors.lastname: Stryjer
authors.forename: Shai
authors.initials: S
authors.lastname: Konas
authors.forename: Rachel
authors.initials: R
authors.lastname: Louis
authors.forename: Haggai
authors.initials: H
authors.lastname: Hermesh
authors.forename: Hanan
authors.initials: H
authors.lastname: Munitz
authors.forename: Abraham
authors.initials: A
authors.lastname: Weizman
authors.forename: Avi
authors.initials: A
authors.lastname: Valevski
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001831:Body Temperature; D016022:Case-Control Studies; D003315:Cornea / Q000187:drug effects / Q000503:physiopathology*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology*; D012565:Schizophrenic Psychology
chemical_list: D014150:Antipsychotic Agents